SPX 304
Alternative Names: SPX-304Latest Information Update: 15 Sep 2023
At a glance
- Originator Sparx Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 08 Sep 2023 SPX 304 is available for licensing as of 08 Sep 2023. https://sparxbio.com/?page_id=3238 (Sparx Therapeutics pipeline, September 2023)
- 08 Sep 2023 Early research in Cancer in USA (Parenteral) before September 2023 (Sparx Therapeutics pipeline, September 2023)